Last updated: 2026-10-13 11:49:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
REGENXBIO Inc. (RGNX) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $7,74, with a market capitalisation of $532,73M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $5,46 to $16,19. This page covers its latest market performance, valuation, price trends and company information.
$532,73M | |
$7,91 | |
$85,10 | |
$5,04 | |
$7,77 | |
2,16K | |
1,48M | |
-- | |
$16,19 | |
$5,46 | |
-- | |
-- |
REGENXBIO Inc. (RGNX) is trading at $7,74 in pre-market trading as of 2026-10-13 11:42:00, down 0,40% ($0,03) from the previous close of $7,77
Pre-market trading shows how investors are pricing RGNX before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, REGENXBIO Inc. (RGNX) moved from $7,43 to $7,74, representing a gain of 4,16% ($0,31).
The stock traded between $7,20 and $8,31 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 1,53 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 21,3%
RGNX is currently trading at $7,74, placing it 21,3% of the way from its 52-week low of $5,46 to its 52-week high of $16,19. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 371 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of REGENXBIO Inc. (RGNX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.